- Home
- DAVE vs ARQT Comparison
DAVE vs ARQT Comparison
Compare DAVE & ARQT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DAVE
- ARQT
- Stock Information
- Founded
- DAVE 2017
- ARQT 2016
- Country
- DAVE United States
- ARQT United States
- Employees
- DAVE N/A
- ARQT N/A
- Industry
- DAVE Retail: Computer Software & Peripheral Equipment
- ARQT Biotechnology: Pharmaceutical Preparations
- Sector
- DAVE Technology
- ARQT Health Care
- Exchange
- DAVE Nasdaq
- ARQT Nasdaq
- Market Cap
- DAVE 3.4B
- ARQT 2.1B
- IPO Year
- DAVE N/A
- ARQT 2020
- Fundamental
- Price
- DAVE $239.32
- ARQT $25.31
- Analyst Decision
- DAVE Strong Buy
- ARQT Strong Buy
- Analyst Count
- DAVE 6
- ARQT 7
- Target Price
- DAVE $265.50
- ARQT $22.17
- AVG Volume (30 Days)
- DAVE 355.1K
- ARQT 2.5M
- Earning Date
- DAVE 11-04-2025
- ARQT 10-28-2025
- Dividend Yield
- DAVE N/A
- ARQT N/A
- EPS Growth
- DAVE 70.95
- ARQT N/A
- EPS
- DAVE 3.84
- ARQT N/A
- Revenue
- DAVE $433,065,000.00
- ARQT $317,929,000.00
- Revenue This Year
- DAVE $50.20
- ARQT $73.37
- Revenue Next Year
- DAVE $15.33
- ARQT $31.36
- P/E Ratio
- DAVE $62.27
- ARQT N/A
- Revenue Growth
- DAVE 47.97
- ARQT 129.21
- 52 Week Low
- DAVE $37.44
- ARQT $8.21
- 52 Week High
- DAVE $286.45
- ARQT $27.08
- Technical
- Relative Strength Index (RSI)
- DAVE 56.21
- ARQT 72.28
- Support Level
- DAVE $223.00
- ARQT $19.60
- Resistance Level
- DAVE $262.32
- ARQT $27.08
- Average True Range (ATR)
- DAVE 17.10
- ARQT 1.26
- MACD
- DAVE 1.90
- ARQT 0.41
- Stochastic Oscillator
- DAVE 65.84
- ARQT 76.34
About DAVE Dave Inc.
Dave Inc is a financial services company. It is engaged in offering banking app that offers its customers banking, financial insights, overdraft protection, building credit and finding side gigs.
About ARQT Arcutis Biotherapeutics Inc.
Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.